Human cytomegalovirus (HCMV), a member of the b-herpesvirus family, is a universal human pathogen. Immunocompetent individuals infected with HCMV are normally asymptomatic or with self-limiting infection [1] . However, primary infections or reactivation can result in significant morbidity and mortality in immunocompromised hosts, such as patients with AIDS [2] and organ/cell transplant recipients [3] . Current preventive or therapeutic medications, such as foscarnet, ganciclovir and cidofovir, are highly effective but do not necessarily lead to better survival of HCMV-infected patients because of the emergence of late-onset HCMV disease or the outgrowth of drug-resistant strains [4] . Toxicities associated with these antiviral agents are also a concern, especially myelosuppression and renal damage [5] . Therefore, alternative approaches for the treatment of HCMV infection are needed and are being developed, such as T-cell therapy for HCMV infections [6] .
RNA interference (RNAi) is a naturally occurring mechanism that is highly conserved in eukaryotes for post-transcriptional gene regulation [7, 8] . Thanks to its high sequence specificity, versatility and efficiency, RNAi might be a good therapeutic modality for preventing or treating viral infections [9] [10] [11] [12] [13] [14] . However, direct introduction of synthesized double-stranded small interfering RNA (siRNA) frequently does not produce a clear RNAi response in mammals, possibly because certain double-stranded RNA sequences may activate an interferon response that masks the RNAi efficacy [15] [16] [17] . An alternative RNAi pathway in animal cells involves introducing a plasmid that expresses a short hairpin RNA (shRNA), which is produced from a single
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The initial design of vector systems produced shRNAs driven by RNA polymerase-III-dependent promoters, such as U6 and H1 [16, 18, 19] . However, in animals, primary micro RNAs (miRNA) are mostly transcribed by RNA polymerase II [20] . After being exported to the cytoplasm, they can be cleaved by Dicer to form the standard 21-mer siRNAs and thus become active in the RNAi pathway [21] .
Evidence from a large-scale study suggested that RNAi processed through a more natural route, such as the second-generation shRNA, may produce more effective silencing [17] . Utilizing the increasing understanding of the elements involved in RNA silencing, Du et al. [22] designed second-generation shRNA vectors pSM30 and pSM155 that improve shRNA processing by placing the miRNA-based artificial miRNA expression cassettes (shRNA-miRs) inside synthetic introns. Based on pSM30, we constructed a series of pSM30-shRNA-miRs that target various transcripts of HCMV and demonstrated that bi-and tricistronic shRNA-miRs yield better virus inhibition. In addition, we showed that coexpression of Argonaute-2 (Ago2) together with a pSM30 plasmid that harbours consecutive shRNAmiRs targeting the HCMV UL46, UL70 and UL122 transcripts, drastically inhibited HCMV replication in human primary embryonic lung fibroblasts.
Methods

Cell culture
Human embryonic lung fibroblast cell line MRC-5 was obtained from the American Type Culture Collection (Manassas, VA, USA). Cells were maintained in minimal essential medium (MEM) supplemented with 2 mM l-glutamine, Earle's balanced salt solution, 0.1 mM non-essential amino acids, 1.0 mM sodium pyruvate and 10% fetal bovine serum. MRC-5 cells at passages 28-31 were used for DNA transfection and viral infection.
Virus preparations
HCMV laboratory strain AD169 was provided by Chuan-Liang Kao (National Taiwan University Hospital, Taipei, Taiwan). AD169 grown on MRC-5 cells was infected at a multiplicity of infection (MOI) of 0.1. Cell-free infectious supernatant was harvested when 70-80% of the fibroblasts showed a cytopathic effect. Virus stocks were supplemented with 35% sorbitol and stored at -80°C. To test if the designed shRNA-miRs would protect MRC-5 cells from viral replication, serum-starved cells transfected with pSM30-shRNA-miRs were infected with AD169 at an MOI of 0.6. At 2 h after infection, the virus inoculum was replaced with fresh medium. Cell supernatants were harvested at day 7 post-infection and subjected to plaque reduction assays.
Plaque reduction assays
Plaque reduction assays [23, 24] were performed to determine the infectivity of HCMV. Aliquots of 4×10 4 MRC-5 cells were seeded in 24-well plates. After 24 h, monolayer cells were serum-starved for an additional 24 h and then infected with cell-free AD169 viral supernatants harvested from MRC-5 cells treated with or without shRNA-miRs. A 10-fold serially diluted virus preparation was added to each well and incubated in a CO 2 incubator at 37°C. At 2 h after infection, 1 ml medium containing 1% methylcellulose, 2% fetal bovine serum, 20 mM HEPES, 0.1 mM NEAA, 1.0 mM sodium pyruvate and 1×MEM was added to each well. After 7 days, the cell monolayer was fixed in ice-cold methanol for 5 min. Viral plaques were stained with 0.03% methylene blue for 30 min and the number of plaques was visualized and counted using a microscope.
Plasmids construction
The parental pSM30-EGFP vector (expressing enhanced green fluorescent protein [EGFP]) for constructing shRNA-miRs was provided by Guangwei Du (The University of Texas Health Science Center at Houston, Houston, TX, USA) [22] . Top and bottom primers carrying a single cassette of the 22-base shRNA sequences targeting UL37 (antiapoptotic), UL46 (capsid), UL54 (DNA polymerase), UL70 (helicase), UL98 (alkaline nuclease) and UL122 (IE2) [25] of HCMV were synthesized ( Figure 1A and Additional file 1). As shown in Figure 1B and Additional file 1, nucleotide sequences that contain 5′-AGCG followed by a 22-base sense sequence of the target gene, the loop sequence TAGTGAAGCCACAGAT-GTA and then a 22-base antisense sequence of the target gene were synthesized. The last nucleotide of the antisense sequence was changed to a nucleotide that did not anneal with the first nucleotide of the sense sequence ( Figure 1B and Additional file 1). The bottom strand was designed by complementary reversion of the 'sense plus loop plus antisense' sequence of the forward primer plus GGCA at the 5′-end (Additional file 1). Hairpin structure of a representative pUL37 shRNA is shown in Figure 1B . The top and bottom strands were annealed and inserted into the BsmBI restriction site of the pSM30-EGFP vector (Figure 2A) .
The cloned shRNA-miRs were flanked with miR30 miRNA sequences (Figure 2A ). To enhance viral inhibitory efficacy, pSM30-EGFP was inserted with ≥2 consecutive shRNA cassettes targeting the aforementioned HCMV transcripts (Figure 2A ). To construct bicistronic shRNA-miRs, the second shRNA-miR cassette was digested with XhoI and MluI, treated with Klenow polymerase and inserted in the MluI site of pSM30-EGFP ( Figure 2A) . Similarly, the third shRNA-miR cassette was digested with XhoI and MluI, filled in using Klenow and cloned into the XhoI restriction site upstream of the first cassette ( Figure 2A ).
Human TARBP2 (that is, TRBP, NM_134324) [26] was amplified by PCR and cloned into the BamHI and XhoI sites of vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) inserted with two FLAG tags between HindIII and KpnI. pIRESneo-FLAG/HA Ago2 was obtained from Addgene (Cambridge, MA, USA) [27] . 
Small RNA isolation and quantification
Small RNAs (≤200 nucleotides) were isolated using mirVana™ miRNA isolation kits (Ambion, Austin, TX, USA). Mature double-stranded siRNAs (that is, UL46-2 and UL122-3) were quantified by a two-step real-time RT-PCR following the protocol provided with the TaqMan ® MicroRNA Assay (Ambion). In brief, 10 ng purified small RNA was reverse transcribed with three specific RT primers: UL46-2 RT primer, 5′-GTCGTATCCAGTGCAGGGTCCGAGG TATTCGCACTGGATACGACTACTAT-3′; UL122-3 RT primer, 5′-GTCGTATCCAGTGCAGGGTCCGA GGTATTCGCACTGGATACGACTCTAAC-3′ and a control small nucleolar RNA RNU44 primer provided with the kit. Reverse transcribed products of UL46-2 and UL122-3 were quantified by real-time PCR using SYBR ® Green I (Takara Bio Inc., Shiga, Japan) in a LightCycler 1.5 (Roche, Basel, Switzerland). RNU44 was quantified using the TaqMan ® MicroRNA Assay kit. Sequences of the forward primers were: UL46-2, 5′-TCGCTAGATAGCGAACCGAT-3′ and UL122-3, 5′-TTCATCCAGTATGCACCAGG-3′. A universal reverse primer: 5′-GTGCAGGGTCCGAGGT-3′ was used in all reactions.
Results
Construction of pSM30-EGFP-based shRNA-miRs targeting HCMV
RNAi has emerged as a powerful approach for silencing gene expression in vivo and in vitro. The recently developed second-generation shRNA-miRs harbouring miRNA sequences flanking the shRNA backbone greatly enhance the efficiency of producing double-stranded siRNA [28] . Applying the second-generation shRNAmiR vector pSM30-EGFP developed by Du et al. [22] [22] . The target sequence of pUL37 is presented. H a r v e s t s u p e r n a t a n t we constructed 10 plasmids that each contained one cassette of shRNA-miR to suppress the expression of various HCMV transcripts (that is, UL37, UL46, UL54, UL70, UL98 and UL122; Additional file 1). The target regions were designed based on the siRNA Design Software algorithm and mfold (version 3.2) [29, 30] . The mfold algorithm was used to avoid structured regions in the target transcripts for better RNAi efficiency [31, 32] and prevention of viral escape [33] . The target regions, as described in the Methods section, are mostly conserved among HCMV strains AD129 (accession number X17403), Towne (accession number FJ616285), Merlin (accession number AY446894) and AF1 (accession number GU179291; Additional file 2). The timeline of the virus infectability assay is presented in Figure 2B . Human embryonic lung MRC-5 fibroblasts were transfected with pSM30-shRNA-miRs, serum-starved for 24 h after 24 h of transfection and then infected with HCMV AD169 strain at an MOI of 0.6. Transfection efficiency was visualized by expression of EGFP. Overall, >47% cells were positive for EGFP at day 2 post-transfection (P-LS et al., data not shown). A pSM30-shRNA-miR that contains a 22-base scrambled sequence was used as a control (Additional file 1). Supernatants were collected 7 days post-infection and subjected to plaque reduction assays. The efficiency of protection of shRNA-miRs against HCMV varied from 0% to 70% (Figure 3) . Three of the shRNA-miRs tested, pUL46-2, pUL-70 and pUL122-3, provided better effects for inhibiting HCMV production (Figure 3 ).
Bicistronic and polycistronic shRNA-miRs show better inhibition of HCMV replication
Because pSM-EGFP is driven by the HCMV polymerase II promoter, it is possible to assemble multiple shRNAmiR cassettes within a single transcript without diluting their inhibitory efficacy [22] . Our initial attempt using a single shRNA-miR cassette did not reach efficient viral suppression; therefore, we designed vectors that contain two or three shRNA-miR cassettes (Figure 2A ) and examined their efficacy in controlling HCMV replication.
Three bicistronic vectors, pUL46+UL122 (containing shRNA-miR cassettes UL46-2 and UL122-3), pUL70+UL122 (containing shRNA-miR cassettes UL70 and UL122-3), pUL46+UL70 (containing shRNA-miR cassettes UL46-2 and UL70) and one tricistronic vector pUL70+UL46+UL122 (containing shRNA-miR cassettes UL70, UL46-2 and UL122-3; Figure 2A ) were constructed and introduced into MRC-5 cells. Cells were then infected with AD169 and viral titres were monitored by plaque reduction assays at 7 days post-infection ( Figure 2B ). Interestingly, pUL46+UL122 and pUL70+UL46+UL122 showed >80% inhibition of HCMV replication, whereas reduced virus protection was observed in cells treated with pUL46+UL70 and pUL70+UL122 ( Figure 4) . Nevertheless, we obtained two formulae (pUL46+UL122 and pUL70+UL46+UL122) with better potency for suppressing HCMV maturation than single shRNA-miRs.
Ago2 augments the efficacy of shRNA-miRs in suppressing HCMV replication Previous reports indicated that components in the miRNA pathway may be limiting factors for the efficiency of RNAi processing in different cells or tissues [34, 35] . A recent study demonstrated that ectopic expression of the RNA-induced silencing complex (RISC) slicer Ago2 enhanced RNAi specifically for messenger RNA (mRNA) targets with perfectly matched binding sites [34] . Because we applied an miRNA backbone flanking the perfectly matched double-stranded RNA in our design, we suspected that coexpression of Ago2 might enhance the maturation of shRNA-miRs and thus augment the efficacy of shRNA-miRs against virus production.
To test this hypothesis, an Ago2 expression vector was cointroduced into MRC-5 cells with the shRNAmiRs pUL46+UL122 and pUL70+UL46+UL122, respectively. Cells were then infected with AD169 and viral titres were quantified by plaque reduction assays, as described. Indeed, replication of virus was reduced by 95 ±0.71% with (pUL46+UL122)+Ago2 and by 87 ±0.71% with (pUL70+UL46+UL122)+Ago2 ( Figure  5A ). In addition, the virus suppression effect increased with expression of Ago2 in a dose-dependent manner ( Figure 5A ). The transactivation response region RNA binding protein (TRBP) has been shown to associate with the RISC and its predecessor, the RISC loading complex [36] . TRBP binds directly to Dicer and to double-stranded RNA and is involved in stabilizing RISC loading complex [37] . TRBP has been shown to affect the efficacy of RNAi in addition to Ago2 [34] . To test whether TRBP might interfere with the activity of shRNA-miRs, we introduced the TRBP expression vector together with pUL46+UL122 or pUL70+UL46+UL122 and examined virus production ( Figure 5B ). Unlike Ago2, TRBP did not augment shRNA-miRs in suppressing HCMV replication ( Figure 5A and 5B).
Coexpression of Ago2 enhances the yield of mature siRNAs
To test whether Ago2 would increase the production of mature siRNA encoded in pSM30-shRNA-miRs, we quantified the copy numbers of mature doublestranded RNA from pUL46+UL122 coexpressed with or without Ago2 by real-time RT-PCR. As shown in Figure 5C and 5D, production of siRNAs directed against UL46-2 and UL122-3 increased with Ago2 expression. Differences in siRNA production between Ago2-untransfected and Ago2-transfected cells were similar at 2, 3 and 4 days post-transfection, suggesting that the transiently overexpressed Ago2 was functional for RNA processing. A slight decrease in the doublestranded RNA yield of UL46-2 and UL122-3 observed at day 4 post-transfection is probably due to reduced molarity of transfected plasmid relative to cell endogenous RNU44 after 4 days of cell divisions.
Discussion
This study confirmed that RNAi could be a good strategy to control HCMV infection. Although RNAi has been pursued actively for treating many viral infections, surprisingly little has been published on siRNA therapy for HCMV infection [38] . This may be related to the difficulty in handling HCMV in vitro because of the need for growth-arrested primary human fibroblasts, in which transfection efficiency and the selection of the sequence to be targeted have to be optimized carefully. To our knowledge, only one report [38] has mentioned using RNAi to control HCMV replication in human primary fibroblasts and the antiviral efficacy was accessed 96 h post-infection. Here, we demonstrated a strategy to inhibit HCMV maturation in a primary cell line MRC-5 up to day 7 post virus infection.
With accumulated knowledge for the RNA silencing pathway, the second generation of shRNA/miRNA expression vectors pSM30 and pSM155 were designed for the efficient expression of multiple RNAi cassettes (that is, shRNA-miRs) within a single plasmid [22] . Here, we demonstrated that pSM30-EGFP-based vectors carrying multiple shRNA-miR cassettes showed an additive effect for inhibiting HCMV replication. Moreover, coexpression of the RNA silencing endonuclease Ago2 enhanced the yields of the shRNA-miR-encoded mature siRNAs, which further strengthened activity of shRNA-miRs for suppressing HCMV production.
Following the strategy of Du et al. [22] , we compared the inhibitory effects of shRNA-miRs targeting various transcripts of HCMV. Ten pSM30-shRNA-miRs were constructed targeting six HCMV transcripts. However, we did not obtain significant viral suppression with all the constructs containing a single shRNA-miR cassette. Because the pSM30 vector allows expression of multiple shRNA-miR cassettes, we assembled UL46-2, UL70 and UL122-3, which showed better individual inhibitory effects and tested whether their activities 
Figure 4. Analyses of antiviral activities of shRNA-miRs containing bicistronic or tricistronic gene cassettes Bicistronic short hairpin RNA (shRNA)-micro RNA (miR) targeting human cytomegalovirus transcripts UL46-2+UL122-3 (that is, pUL46+UL122), UL70+UL122-3 (that is, pUL70+UL122), UL70+UL46-2 (that is, pUL70+UL46) and a tricistronic shRNA-miR that contain target gene sequences of UL70+UL46-2+UL122-3 (that is, pUL70+UL46+UL122) were constructed. Antiviral activities of these plasmids were tested by plaque reduction assays. Data were obtained from triplicate experiments and are indicated as the mean ±sd.
could be improved by combination. Unexpectedly, while pUL46+UL122 and pUL70+UL46+UL122 showed increased suppression, reduced activities were observed with pUL70+UL122 and pUL70+UL46. It seems that assembling multiple shRNA-miRs does not necessarily warrant improved activity. We hypothesize that secondary structures or motifs of individual shR-NA-miR cassette might interfere with each other and thus affect the maturation efficiency of siRNA when multiple cassettes are linked side by side [39] . Because the prediction algorithm for Dicer or Ago2-preferred secondary/tertiary structure of RNA hairpins is currently unavailable [40, 41] , experimental validation is still required for the design of multiplex shRNA-miRs. One major obstacle for the treatment of viral infections using RNAi is that viruses frequently develop mutations that can escape by selection of a point mutation in the target sequence [16, 33, 42] . In the tricistronic shRNA-miRs constructed in this study, the pUL70+UL46+UL122 vector allows for the simultaneous production of shRNAs specific for capsid, helicase/primase and the IE2 region of HCMV. Thus, using multiplex shRNA-miRs might prevent the virus from escaping. In addition to the pSM30 system, several strategies have been created to produce multiple targeting siRNAs to prevent emergence of escape viral variants [43] . The success designs include extended shRNA [44, 45] that comprise two or three effective siRNAs transcribed with polymerase III promoters, multiplex siRNAs that contain polycistronic miRNA-like transcripts [46, 47] driven by an HCMV promoter, double long hairpin RNAs [48] with U6 promoter and a lentiviral vector contains four shRNA expression cassettes placed in tandem driven by human polymerase III promoters U6, H1 and 7SK and the polymerase II U1 promoter, respectively [49] . Of note, ter Brake et al. [49] provide a solid demonstration that multiple RNAi attacks indeed avoid the evolution of resistant viruses. Collectively, these efforts, along with this report, enlighten developing clinical antiviral therapeutics using the combinatorial RNAi technology [43] .
During the post-transcriptional pathway of gene silencing [20] , the transcribed pre-miRNAs are first processed in the nucleus by Drosha into pre-miRNAs (60-80 nucleotides) and transported to the cytoplasm with the assistance of exportin-5. These primary miRNAs are cleaved by the RNase III Dicer to generate mature miRNAs that direct RISC to messenger RNAs with complementary sequence. Ago2 and TRBP are both components of RISC and have been shown to improve the efficiency of RNAi in cells that have limited abundancy. Applying this concept, we coexpressed Ago2 and TRBP with shRNA-miRs and expected increased production of mature siRNAs and thus improved virus silencing. In our experiments, Ago2 functioned positively both in siRNA yield and virus inhibition as expected, whereas TRBP did not interfere with virus production ( Figure 5A and 5B). Because Ago2 participates in endogenous miRNA biogenesis in addition to acting as an effector for targeting mRNA cleavage [34] , the advantage of Ago2 over TRBP may arise from its dual roles in RNA silencing.
Are bicistronic shRNA-miRs processed equally to become mature siRNAs? As shown in Figure 5C and 5D, although UL46-2 and UL122-3 were transcribed simultaneously, the yield of the resulting UL46-2 and UL122-3 siRNAs differed. Quantitative RT-PCR revealed approximately 40× more copies of UL46-2 siRNAs than for UL122-3. Intriguingly, Ago2 overexpression improved the production of siUL122-3 more than siUL46-2. These results suggest that excess Ago2 may enhance production of double-stranded RNA from shRNAs that are less favoured with endogenous abundancy.
In conclusion, we have developed an effective shRNA therapy to suppress HCMV replication. The combination of single shRNAs in lieu of a second generation of shRNA-miRs can achieve additive efficacy compared with single shRNAs. This successful approach is potentially useful to deal with viral escape mutants. We believe the methodologies established here can help develop clinical approaches for treating HCMV or other viral infections.
